Asset Details
Do you wish to reserve the book?
The epidemiology of hepatitis C virus in Central Asia: Systematic review, meta-analyses, and meta-regression analyses
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The epidemiology of hepatitis C virus in Central Asia: Systematic review, meta-analyses, and meta-regression analyses
Do you wish to request the book?
The epidemiology of hepatitis C virus in Central Asia: Systematic review, meta-analyses, and meta-regression analyses
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The epidemiology of hepatitis C virus in Central Asia: Systematic review, meta-analyses, and meta-regression analyses
2019
Overview
The objective was to delineate hepatitis C virus (HCV) epidemiology in countries of Central Asia (CA), specifically Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, and Uzbekistan. A systematic review was conducted guided by the Cochrane Collaboration Handbook, and reported using PRISMA guidelines. Meta-analyses were performed using DerSimonian-Laird random-effects models with inverse variance weighting. Random-effects meta-regression analyses were performed on general population studies. The systematic review identified a total of 208 HCV prevalence measures. No incidence or Turkmenistan studies were identified. Meta-analyses estimated HCV prevalence among the general population at 0.7% (95%CI: 0.7–0.8%) in Kazakhstan, 2.0% (95%CI: 1.7–2.4%) in Kyrgyzstan, 2.6% (95%CI: 1.7–3.6%) in Tajikistan, and 9.6 (95%CI: 5.8–14.2%) in Uzbekistan. Across CA, the pooled mean prevalence was 13.5% (95%CI: 10.9–16.4%) among non-specific clinical populations, 31.6% (95%CI: 25.8–37.7%) among populations with liver-related conditions, and 51.3% (95%CI: 46.9–55.6%) among people who inject drugs. Genotypes 1 (52.6%) and 3 (38.0%) were most frequent. Evidence was found for statistically-significant differences in prevalence by country, but not for a temporal decline in prevalence. CA is one of the most affected regions by HCV infection with Uzbekistan enduring one of the highest prevalence levels worldwide. Ongoing HCV transmission seems to be driven by injecting drug use and healthcare exposures.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
